Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/109459
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Passadouro, Marta | - |
dc.contributor.author | Lima, Maria C. Pedroso de | - |
dc.contributor.author | Faneca, Henrique | - |
dc.date.accessioned | 2023-10-16T10:54:35Z | - |
dc.date.available | 2023-10-16T10:54:35Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1178-2013 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/109459 | - |
dc.description.abstract | Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and mortal cancer, characterized by a set of known mutations, invasive features, and aberrant microRNA expression that have been associated with hallmark malignant properties of PDAC. The lack of effective PDAC treatment options prompted us to investigate whether microRNAs would constitute promising therapeutic targets toward the generation of a gene therapy approach with clinical significance for this disease. In this work, we show that the developed human serum albumin-1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine:cholesterol/anti-microRNA oligonucleotides (+/-) (4/1) nanosystem exhibits the ability to efficiently deliver anti-microRNA oligonucleotides targeting the overexpressed microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. Silencing of these microRNAs resulted in a significant increase in the levels of their targets. Moreover, the combination of microRNA silencing, namely miR-21, with low amounts of the chemotherapeutic drug sunitinib resulted in a strong and synergistic antitumor effect, showing that this combined strategy could be of great importance for therapeutic application in PDAC. | pt |
dc.language.iso | eng | pt |
dc.publisher | Dove Medical Press | pt |
dc.relation | PTDC/SAU-BMA/114482/2009 | pt |
dc.relation | PEst-C/SAU/LA0001/2013–2014 | pt |
dc.relation | SFRH/BD/46903/2008 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt |
dc.subject | pancreatic cancer gene therapy | pt |
dc.subject | anti-microRNAs oligonucleotides | pt |
dc.subject | delivery nanosystems | pt |
dc.subject | albumin-associated lipoplexes | pt |
dc.subject.mesh | Antineoplastic Agents | pt |
dc.subject.mesh | Carcinoma, Pancreatic Ductal | pt |
dc.subject.mesh | Cell Line, Tumor | pt |
dc.subject.mesh | Cell Survival | pt |
dc.subject.mesh | Drug Synergism | pt |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | pt |
dc.subject.mesh | Genetic Therapy | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Indoles | pt |
dc.subject.mesh | MicroRNAs | pt |
dc.subject.mesh | Oligonucleotides, Antisense | pt |
dc.subject.mesh | Pancreatic Neoplasms | pt |
dc.subject.mesh | Phosphatidylcholines | pt |
dc.subject.mesh | Pyrroles | pt |
dc.subject.mesh | Sunitinib | pt |
dc.subject.mesh | Transfection | pt |
dc.title | MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer | pt |
dc.type | article | - |
degois.publication.firstPage | 3203 | pt |
degois.publication.lastPage | 3217 | pt |
degois.publication.title | International Journal of Nanomedicine | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.2147/IJN.S64456 | pt |
degois.publication.volume | 9 | pt |
dc.date.embargo | 2014-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0003-1844-5027 | - |
Appears in Collections: | FCTUC Ciências da Vida - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
MicroRNA-modulation-combined-with-sunitinib-as-a-novel-therapeutic-strategy-for-pancreatic-cancerInternational-Journal-of-Nanomedicine.pdf | 1.84 MB | Adobe PDF | View/Open |
Page view(s)
44
checked on May 8, 2024
Download(s)
22
checked on May 8, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License